Ebopiprant (also known as OBE022) is an orally bioavailable, selective small molecule antagonist of the prostaglandin F2α receptor.
Inhibition of this receptor could reduce uterine inflammation and contractions, preventing cervical changes and membrane ruptures that occur in pre-term labor.
In a Phase 2a, double-blind, parallel group, randomized, placebo-controlled trial (PROLONG) conducted in Europe and Asia, ebopiprant demonstrated proof of concept in delaying preterm birth on top of standard of care, with a potential improved safety profile over NSAIDs, pan-inhibitors of prostaglandin synthesis.